Ainnocence Inc Press Releases

• Published on May 8, 2025 - 18:58 GMT

  

  Ainnocence Unveils Core Challenges Undermining AI-Driven Small-Molecule Drug Discovery

  How current methodologies fail to address critical challenges in early stage drug discovery. SAN FRANCISCO, CA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- Ainnocence, a leader in next-generation AI drug-discovery solutions, today released a …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on April 14, 2025 - 21:03 GMT

  Obatala Sciences and Ainnocence Announce Partnership to Transform Drug Discovery Through AI and Human Biological Models

  MOUNTAIN VIEW, CA, UNITED STATES, April 14, 2025 /⁨EINPresswire.com⁩/ -- Highlights: • Obatala Sciences and Ainnocence’s groundbreaking partnership addresses the FDA’s recent call for human-relevant methods for new drug development. • The partnership …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on February 18, 2025 - 15:51 GMT

  Ainnocence Achieves 10,000x Reduction in Computational Cost for Protein Design Without 3D Modeling

  SAN FRANCISCO, CA, UNITED STATES, February 18, 2025 /⁨EINPresswire.com⁩/ -- Ainnocence, a leader in AI-driven drug discovery, has achieved a breakthrough in protein design, slashing computational costs by over 10,000x through its sequence-based AI approach …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on January 29, 2025 - 20:08 GMT

  Ainnocence Demonstrates Breakthrough AI Technology for Rapid Pandemic Response

  SAN FRANCISCO, CA, UNITED STATES, January 29, 2025 /⁨EINPresswire.com⁩/ -- Ainnocence has achieved significant milestones in applying artificial intelligence to accelerate antibody discovery for pandemic preparedness, demonstrating unprecedented speed and …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on January 6, 2025 - 21:00 GMT

  Advanced Generative AI Platform Achieves Computational Efficiency Breakthrough in Therapeutic Protein Engineering

  SAN FRANCISCO, CA, UNITED STATES, January 6, 2025 /⁨EINPresswire.com⁩/ -- Ainnocence Inc. introduces its breakthrough generative AI platform fundamentally transforming therapeutic protein engineering by eliminating traditional computational bottlenecks in …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on November 25, 2024 - 14:24 GMT

  AI Breakthrough Ushers in New Era of Personalized Medicine

  SAN FRANCISCO, CA, UNITED STATES, November 25, 2024 /⁨EINPresswire.com⁩/ -- AI Biotechnology company Ainnocence is transforming healthcare through AI-driven advances in antibody, cell, and gene therapy design. Their proprietary third-generation …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on November 11, 2024 - 17:00 GMT

  Turbocharging Drug Discovery: AI-Powered R&D is Transforming the Pharmaceutical Industry and Accelerating Breakthroughs

  SAN FRANCISCO, CA, UNITED STATES, November 11, 2024 /⁨EINPresswire.com⁩/ -- In a landmark shift that's revolutionizing pharmaceutical research and development, artificial intelligence is dramatically reshaping how we discover and develop new drugs. …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on October 28, 2024 - 16:00 GMT

  Revolutionizing Molecular Design beyond 3D modeling: Innovative R&D in Protein Language Models Unlocks New Frontiers

  SAN FRANCISCO, CA, UNITED STATES, October 28, 2024 /⁨EINPresswire.com⁩/ -- Ainnocence, a pioneering AI-driven biotech company, is pushing the boundaries of molecular design with its next-generation protein engineering platform, setting a new standard for …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on October 7, 2024 - 18:00 GMT

  Ainnocence Unveils Advanced AAV Design Services to Revolutionize Gene Therapy

  SAN FRANCISCO, CA, UNITED STATES, October 7, 2024 /⁨EINPresswire.com⁩/ -- Ainnocence, a next-generation biotech company, is proud to announce the launch of its cutting-edge AAV (Adeno-Associated Virus) design services, powered by the SentinusAI® platform. …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on September 3, 2024 - 18:00 GMT

  

  AINNOCENCE LAUNCHES CellulaAI™: A Pioneering AI Engine to Revolutionize CAR-T Therapy

  BIRMINGHAM, ALABAMA, UNITED STATES, September 3, 2024 /⁨EINPresswire.com⁩/ -- Ainnocence Inc., a leader in AI-driven biotech solutions, is proud to announce the launch of CellulaAI™, an innovative AI engine designed to transform the landscape of CAR-T …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on August 5, 2024 - 19:00 GMT

  

  Ainnocence Unveils SentinusAI®: Revolutionizing Antibody Design, Conquering Undruggable Targets, Rescuing Failed Trials

  Transforming Cancer Immunotherapies with AI-Driven Discovery and Optimization SAN FRANCISCO, CALIFORNIA, UNITED STATES, August 5, 2024 /⁨EINPresswire.com⁩/ -- Ainnocence today announced the launch of SentinusAI®, a groundbreaking AI platform for precision …

  Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...
• Published on May 6, 2024 - 15:00 GMT

  

  Ainnocence Embraces Green AI and Animal-Free Drug Screening: A Dual Commitment to Sustainable and Ethical Innovation

  SAN FRANCISCO, CALIFORNIA, U.S., May 6, 2024 /⁨EINPresswire.com⁩/ -- Ainnocence is proud to announce its strategic focus on highly sustainable and ethical applications in AI and biotechnology. With its commitment to Green AI and animal free drug discovery …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on December 5, 2023 - 14:00 GMT

  

  Ainnocence Unveils Innovative AI-enabled Platform for Antibody Affinity Maturation and GPCR Antibody Design Platform

  Ainnocence unveils AI for antibody affinity and GPCR design via SentinusAI®. Mapping 59 GPCR families, 175 targets, and 444 indications for advanced drug design SAN FRANCISCO , CALIFORNIA, UNITED STATES, December 5, 2023 /⁨EINPresswire.com⁩/ -- Ainnocence …

  Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...
• Published on September 19, 2023 - 21:34 GMT

  AI-Powered Fast and Cost-Effective Antibody De Novo Design and Affinity Maturation Service Unveiled

  Revolutionary AI Technology Transforms Antibody Development and Optimization SAN FRANCISCO , CALIFORNIA , UNITED STATES, September 19, 2023 /⁨EINPresswire.com⁩/ -- AI-Powered Fast and Cost-Effective Antibody De Novo Design and Affinity Maturation Service …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...